Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Work In Process (2023 - 2025)

Catalyst Pharmaceuticals' Work In Process history spans 3 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Work In Process rose 12.37% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, up 12.37%, while the annual FY2025 figure was $3.9 million, 12.37% up from the prior year.
  • Work In Process reached $3.9 million in Q4 2025 per CPRX's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $5.3 million in Q2 2025 to a low of $3.4 million in Q4 2024.
  • Average Work In Process over 3 years is $4.2 million, with a median of $4.1 million recorded in 2024.
  • Peak YoY movement for Work In Process: decreased 24.67% in 2024, then soared 32.89% in 2025.
  • A 3-year view of Work In Process shows it stood at $4.6 million in 2023, then fell by 24.67% to $3.4 million in 2024, then increased by 12.37% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Work In Process are $3.9 million (Q4 2025), $4.6 million (Q3 2025), and $5.3 million (Q2 2025).